Recent research have centered on the convergence of glucagon-like peptide-1|glucose-dependent insulinotropic polypeptide|GCGR stimulant therapies and DA neurotransmission. While GLP agonists are increasingly employed for addressing type 2 diabetes, their potential consequences on reinforcement circuits, specifically influenced by dopaminergic syste